share_log

8-K: Current report

SEC ·  Dec 6, 2024 22:25

Summary by Moomoo AI

Nukkleus has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD on December 3, 2024, enabling the company to sell up to $10 million of common stock shares. The investor agreed to provide $2 million in convertible promissory notes through three tranches, with the first $0.5 million disbursed immediately. The purchase price for shares under SEPA will be 97% of the lowest daily VWAP over three trading days.The convertible notes carry a 10% annual interest rate, increasing to 18% upon default, with a 12-month maturity. The conversion price is the lower of $2.00 or 90% of the lowest daily VWAP over ten trading days, with a $0.33 floor price. The agreement includes provisions for monthly payments of $150,000 plus 10% premium if certain trigger events occur.Separately, Nukkleus received notice on November 26, 2024, that Nasdaq's delisting action has been stayed pending a hearing scheduled for January 21, 2025. The company's securities will continue trading on Nasdaq Global Market until a final decision is reached, though continued listing is not guaranteed.
Nukkleus has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD on December 3, 2024, enabling the company to sell up to $10 million of common stock shares. The investor agreed to provide $2 million in convertible promissory notes through three tranches, with the first $0.5 million disbursed immediately. The purchase price for shares under SEPA will be 97% of the lowest daily VWAP over three trading days.The convertible notes carry a 10% annual interest rate, increasing to 18% upon default, with a 12-month maturity. The conversion price is the lower of $2.00 or 90% of the lowest daily VWAP over ten trading days, with a $0.33 floor price. The agreement includes provisions for monthly payments of $150,000 plus 10% premium if certain trigger events occur.Separately, Nukkleus received notice on November 26, 2024, that Nasdaq's delisting action has been stayed pending a hearing scheduled for January 21, 2025. The company's securities will continue trading on Nasdaq Global Market until a final decision is reached, though continued listing is not guaranteed.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more